161 related articles for article (PubMed ID: 7728774)
1. Combination of highly purified human leukocyte interferon alpha and 13-cis-retinoic acid for the treatment of metastatic melanoma.
Fierlbeck G; Schreiner T; Rassner G
Cancer Immunol Immunother; 1995 Mar; 40(3):157-64. PubMed ID: 7728774
[TBL] [Abstract][Full Text] [Related]
2. Evaluation on serum 2'-5'oligoadenylate synthetase (2'-5'oligoAS) and beta 2 microglobulin (B2M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN-alpha 2A.
Martinetti A; Seregni E; Belli F; Mazzocchi A; Agresti R; Cascinelli N; Greco M; Bombardieri E
Anticancer Res; 1998; 18(3B):2027-30. PubMed ID: 9677461
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and immunological responses of hairy cell leukemia patients to interferon beta.
Liberati AM; Horisberger M; Schippa M; Di Clemente F; Fizzotti M; Filippo S; Proietti MG; Arzano S; Berruto P; Palmisano L
Cancer Immunol Immunother; 1991; 34(2):115-22. PubMed ID: 1760815
[TBL] [Abstract][Full Text] [Related]
4. Isotretinoin and recombinant interferon alfa-2a therapy of metastatic malignant melanoma.
Triozzi PL; Walker MJ; Pellegrini AE; Dayton MA
Cancer Invest; 1996; 14(4):293-8. PubMed ID: 8689422
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
[TBL] [Abstract][Full Text] [Related]
6. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
[TBL] [Abstract][Full Text] [Related]
7. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma.
Dhingra K; Papadopoulos N; Lippman S; Lotan R; Legha SS
Invest New Drugs; 1993 Feb; 11(1):39-43. PubMed ID: 8349434
[TBL] [Abstract][Full Text] [Related]
9. In vivo induction of the interferon-stimulated protein 2'5'-oligoadenylate synthetase in tumor and peripheral blood cells during IFN-alpha treatment of metastatic melanoma.
Grandér D; Sangfelt O; Skoog L; Hansson J
J Interferon Cytokine Res; 1998 Sep; 18(9):691-5. PubMed ID: 9781807
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of recombinant alpha 2b interferon and 13 cis retinoic acid in patients with metastatic melanoma.
Rosenthal MA; Oratz R
Am J Clin Oncol; 1998 Aug; 21(4):352-4. PubMed ID: 9708632
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study.
Ruotsalainen T; Halme M; Isokangas OP; Pyrhönen S; Mäntylä M; Pekonen M; Sarna S; Joensuu H; Mattson K
Anticancer Drugs; 2000 Feb; 11(2):101-8. PubMed ID: 10789592
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
13. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
15. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
Tsimberidou AM; Giles F; Romaguera J; Duvic M; Kurzrock R
Cancer; 2004 Feb; 100(3):574-80. PubMed ID: 14745875
[TBL] [Abstract][Full Text] [Related]
16. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma.
Khayat D; Borel C; Tourani JM; Benhammouda A; Antoine E; Rixe O; Vuillemin E; Bazex PA; Thill L; Franks R
J Clin Oncol; 1993 Nov; 11(11):2173-80. PubMed ID: 8229131
[TBL] [Abstract][Full Text] [Related]
17. A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers.
Dunst J; Hänsgen G; Krause U; Füchsel G; Köhler U; Becker A
Strahlenther Onkol; 1998 Nov; 174(11):571-4. PubMed ID: 9830438
[TBL] [Abstract][Full Text] [Related]
18. 13-cis retinoic acid in combination with interferon-alpha enhances radiation sensitivity of human squamous cell carcinoma cells of the oral cavity.
Bläse M; Zaruba MM; Santo-Hoeltje L; Bamberg M; Hoffmann W; Rodemann HP
Strahlenther Onkol; 1999 Nov; 175(11):563-8. PubMed ID: 10584127
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta.
Fierlbeck G; Schreiner T; Schaber B; Walser A; Rassner G
Cancer Immunol Immunother; 1994 Oct; 39(4):263-8. PubMed ID: 7954528
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
